Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.1%

5 terminated/withdrawn out of 31 trials

Success Rate

78.3%

-8.2% vs industry average

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

0%

0 of 18 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
16(80.0%)
Phase 4
2(10.0%)
Phase 1
2(10.0%)
20Total
N/A(16)
Phase 4(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials
NCT06302400Not ApplicableTerminated

Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT05451862Not ApplicableTerminated

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.

Role: lead

NCT05705973Active Not Recruiting

Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Role: lead

NCT05911633Not ApplicableRecruiting

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Role: lead

NCT02939924Not ApplicableCompleted

Treatment of Patients With Lesions in the Superficial Femoral and/ or Popliteal Arteries Using Kanshas Paclitaxel-coated Balloon Catheter.

Role: lead

NCT04546477Not ApplicableActive Not Recruiting

Prospective Multicenter Study to Confirm the Performance of the Renzan Stent in Treatment of SFA/POP Artery Disease

Role: lead

NCT05643391Not ApplicableCompleted

Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT05335525Unknown

Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

Role: lead

NCT03504228Completed

Prospective Single Arm CAS - ROADSAVER Study

Role: lead

NCT05592171Not ApplicableUnknown

Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC

Role: collaborator

NCT05027698Completed

Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study

Role: lead

NCT05111795Completed

Holmium-166 Retrospective Collection of Real-World Data

Role: lead

NCT04171570Not ApplicableCompleted

DIStal Versus COnventional RADIAL Access for Coronary Angiography and Intervention

Role: lead

NCT04231929Not ApplicableWithdrawn

BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.

Role: lead

NCT03563274Terminated

QuiremSpheres Observational Study

Role: lead

NCT03846752Not ApplicableCompleted

Complex Large-bore Radial Percutaneous Coronary Intervention (PCI) Trial

Role: collaborator

NCT03053596Completed

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

Role: lead

NCT02548780Not ApplicableCompleted

LifePearl-Doxo Pharmacokinetic (PK) Study

Role: lead

NCT01261273Completed

e-NOBORI Observational Registry of Nobori DES

Role: lead

NCT01004575Not ApplicableCompleted

Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease

Role: lead